Patients with HNF1A- and HNF4A-MODY often respond well to sulfonylureas and can discontinue insulin, whereas GCK-MODY generally requires no pharmacologic therapy (Table 3). For this reason, clinical suspicion of MODY should remain in the physician’s mind when seeing patients presenting with hyperglycemia, especially in those under 30 years of age, both in primary and secondary care [4-13]. The gene discussed is INS; the disease is MODY.